Payment overview · 2025
General Payments
$847.87
40 reported records · 15 companies
Healthcare provider profile · identity verified
Paul Edward Kramer, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROSEVILLE, CA · NPI 1790794048
Verified facts
What the public records show
CMS Open Payments records show Paul Edward Kramer, MD received $847.87 in general payments during 2025 across 40 reported records.
PFIZER INC. accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $197.21 | 23.3% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.71 | 12.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $107.29 | 12.7% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.35 | 7.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.99 | 6.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.76 | 6.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.49 | 5.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $41.97 | 5.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.64 | 4.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.46 | 3.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $27.55 | 3.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.19 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.18 | 2.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.99 | 2.1% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $14.09 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $847.87 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $143.31 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $85.61 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $67.53 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.05 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.05 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $56.99 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $56.70 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $53.90 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $53.90 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $53.90 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.76 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.76 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $41.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.66 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $41.64 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $30.46 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.74 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 151 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 97 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 99 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
86 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
99 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
151 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 523 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 420 | 112 |
| Lisinopril | Lisinopril | 393 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 269 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 60 |
| Losartan Potassium | Losartan Potassium | 211 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 62 |
| Sertraline Hcl | Sertraline Hcl | 202 | 48 |
| Simvastatin | Simvastatin | 194 | 53 |
| Trazodone Hcl | Trazodone Hcl | 169 | 40 |
| Alprazolam | Alprazolam | 167 | 40 |
| Eliquis | Apixaban | 151 | 33 |
| Metformin Hcl Er | Metformin Hcl | 150 | 43 |
| Gabapentin | Gabapentin | 137 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 37 |
| Furosemide | Furosemide | 120 | 32 |
| Valsartan | Valsartan | 104 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 22 |
| Mounjaro | Tirzepatide | 99 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 51 |
| Jardiance | Empagliflozin | 97 | 26 |
| Allopurinol | Allopurinol | 95 | 25 |
| Omeprazole | Omeprazole | 95 | 30 |
| Finasteride | Finasteride | 92 | 24 |
| Potassium Chloride | Potassium Chloride | 88 | 25 |
| Synthroid | Levothyroxine Sodium | 86 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 26 |
| Meloxicam | Meloxicam | 82 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 25 |
| Trulicity | Dulaglutide | 74 | 18 |
| Lorazepam | Lorazepam | 72 | 17 |
| Tramadol Hcl | Tramadol Hcl | 66 | 16 |
| Azithromycin | Azithromycin | 63 | 55 |
| Alendronate Sodium | Alendronate Sodium | 61 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 22 |
| Ibuprofen | Ibuprofen | 61 | 24 |
| Metformin Hcl | Metformin Hcl | 59 | 17 |
| Bupropion Xl | Bupropion Hcl | 55 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | suppressed |
| Pregabalin | Pregabalin | 52 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 17 |
| Atenolol | Atenolol | 47 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 28 |
| Estradiol | Estradiol | 44 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Ozempic | Semaglutide | 42 | suppressed |
| Acyclovir | Acyclovir | 40 | 17 |
| Celecoxib | Celecoxib | 40 | 12 |
| Montelukast Sodium | Montelukast Sodium | 40 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 12 |
| Tadalafil | Tadalafil | 40 | suppressed |
| Carvedilol | Carvedilol | 38 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 13 |
| Lovastatin | Lovastatin | 36 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 14 |
| Glipizide | Glipizide | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 31 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Prednisone | Prednisone | 30 | 17 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | 11 |
| Cephalexin | Cephalexin | 27 | 23 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 15 |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 11 |
| Digoxin | Digoxin | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Naproxen | Naproxen | 21 | 13 |
| Amoxicillin | Amoxicillin | 20 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 15 |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $847.87 · 40 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, JARDIANCE, JATENZO, JOURNAVX, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, Wegovy, XYOSTED, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error